Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today announced the availability of Emerging Markets PatientBase, an epidemiological database that provides current and 10-year forecasts of patient populations for the most commercially significant indications across the BRIC (Brazil, Russia, India, China) markets. Combining Decision Resources' epidemiology expertise and extensive knowledge of the major emerging pharmaceutical markets, Emerging Markets PatientBase allows users to estimate current and future patient population sizes for the national patient population of each indication covered, as well as for many specific patient subpopulations. For example, coverage of clinical subpopulations for breast cancer includes analyses by stage at diagnosis, line of therapy and biomarker status.
By providing the total, diagnosed and drug-treated patient population sizes in key emerging markets for major drug indications such as asthma and hepatitis C virus, Emerging Markets PatientBase offers a reliable set of patient population estimates from which pharmaceutical companies can make projections of patient share or market value for given drug indications. In addition to providing diagnosed and drug-treated status, comprehensive analysis in Emerging Market PatientBase includes stratification of the patient population by relevant clinical variables such as severity as well as urban or rural status for markets like China and India.
"Estimating patient populations in emerging markets is time- and resource-intensive and publicly available data sources may not be as robust for emerging markets as they are for more developed markets," said Michael Hughes, Ph.D., principal epidemiologist with Decision Resources. "For companies exploring opportunities in the BRIC countries, Emerging Markets PatientBase provides a comprehensive forecast of patient populations to help drug marketers understand how many patients in the major emerging markets will benefit from being treated with a drug now as well as ten years from now, as well as how many patients are diagnosed and drug-treated."
Emerging Markets PatientBase Indications -- Alzheimer's Disease -- Asthma -- Breast Cancer -- Colorectal Cancer -- Chronic Obstructive Pulmonary Disease -- Dyslipidemia -- Esophageal Cancer -- Gastric Cancer -- Hepatocellular Carcinoma -- Hepatitis B Virus -- Hepatitis C Virus -- Hypertension -- Major Depression -- Non-Small-Cell Lung Cancer -- Prostate Cancer -- Renal Cell Carcinoma -- Rheumatoid Arthritis -- Small-Cell Lung Cancer -- Type 2 Diabetes About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Lisa Osgood Christopher Comfort 781-296-2606 781-296-2597 firstname.lastname@example.org email@example.com
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Lisa Osgood of Decision Resources, +1-781-296-2606,
firstname.lastname@example.org; or Christopher Comfort of Decision Resources, Inc.,
Web Site: http://www.decisionresources.com/